Editorial Policy

Why this page exists

Mammologix publishes content about breast imaging operations, MQSA compliance, patient tracking, follow-up navigation, and clinical performance measurement. Some of that content touches subjects where being wrong has consequences: regulatory requirements, audit methodology, follow-up intervals, and the language facilities use to communicate results to patients.

So we think you should be able to see how it gets made.

This page describes who writes our content, who reviews it, what sources we rely on, how we handle corrections, and where artificial intelligence fits into the process. It applies to everything published under the Mammologix name: Knowledge Hub articles, the MammoTrack, MammoCommunicate, MammoNavigate, and MammoComply knowledge bases, Beyond the Mammogram stories, white papers, LinkedIn posts, and downloadable resources.

Who produces this content

Mammologix has supported breast imaging facilities since 1995. Our content comes from people who do this work, not from a general-purpose content team writing about an industry from the outside.

Founder and President

Richard Lippert founded Mammologix in 1995 after training and working clinically in radiologic technology and mammography. He has more than 30 years of experience in breast imaging program operations, medical outcome auditing, and MQSA compliance.

Operations and analytics staff

Content that describes audit methodology, tracking workflows, reporting logic, or navigation prioritization is written or reviewed by the Mammologix staff who build and run those processes for client facilities.

Editorial Board

Board structure and named members to be published. For each member: name, credential, role, and area of review responsibility.

Authorship is attributed. Where an article has been reviewed by someone other than the author, that reviewer is named.

What we do not do

Being clear about scope is part of being trustworthy.

Mammologix does not read images, assign BI-RADS^® assessments, determine breast density, or substitute for the interpreting physician. Our published content reflects that same boundary. We write about operational process, regulatory requirements, measurement methodology, and workflow design. We do not publish clinical interpretation guidance, diagnostic recommendations, or treatment advice.

When our content describes clinical concepts, it does so to explain the operational or regulatory context around them, and it points to the governing clinical source rather than substituting our judgment for it.

Content risk tiers

Not every piece of content carries the same risk, and treating a workflow tip like a regulatory interpretation wastes review capacity where it matters. Mammologix classifies published content into three tiers, and the required review scales with the tier.

Tier 1: General and operational

Workflow observations, industry commentary, product explanation, and practice-management topics with no clinical or regulatory claim. Requires author accuracy check and editorial review.

Tier 2: Regulatory and methodological

Content that interprets MQSA requirements, FDA guidance, ACR accreditation standards, audit methodology, or performance benchmark definitions. Requires primary-source verification against the governing regulation or standard, plus review by a qualified subject matter reviewer.

Tier 3: Clinical-adjacent

Content that references screening intervals, follow-up recommendations, diagnostic pathways, density notification language, or outcome definitions drawn from clinical guidelines. Requires primary-source citation, subject matter review, and a documented currency check against the governing guideline before publication.

Every Tier 2 and Tier 3 article carries a visible review attribution and a last-reviewed date.

Sourcing standards

We cite primary sources. That means the regulation, the guideline, the peer-reviewed study, or the federal register notice itself, not a secondary article summarizing it.

For regulatory content, we cite the Code of Federal Regulations, FDA guidance documents, MQSA policy guidance, the Federal Register, or official FDA program materials. For clinical context, we cite NCCN guidelines, ACR practice parameters and BI-RADS^®, USPSTF recommendations, or peer-reviewed literature. For statistical claims, we cite the study, including sample size and publication date.

Where a figure comes from Mammologix’s own operational data, we say so plainly and describe what it measures. We do not present internal data as though it were published research.

Regulatory content is dated. Requirements change, and an article that was accurate in 2024 may not be accurate now. Our regulatory articles state the date on which the requirement was verified and are rescreened on the review cycle described below.

Editorial independence

Mammologix is a commercial company, and much of what we publish relates to work we are paid to do. We think the honest way to handle that is disclosure rather than pretending otherwise.

We do not accept payment to publish content, and no advertiser, vendor, or third party influences what we write or how we write it. Where an article discusses a category of service that Mammologix provides, that relationship is disclosed within the article.

Content that promotes a Mammologix service is labeled as such and is kept distinct from educational and regulatory content.

Artificial intelligence use disclosure

Mammologix uses AI assistance in the production of published content. We would rather tell you that directly than bury it.

Here is what that means in practice.

Where AI is used

Drafting support, structural organization, editing, grammatical and stylistic review, formatting, and summarization. AI tools may also be used to help locate source material for subsequent human verification.

Where AI is not used

AI does not make editorial decisions, does not determine what Mammologix publishes, and is not treated as a source. Regulatory interpretations, methodological claims, clinical references, and statistical figures are verified by a human against the primary source before publication. An AI tool’s assertion that a requirement exists is never sufficient basis for publishing that the requirement exists.

Accountability

All AI-assisted work is produced under Mammologix editorial governance and reviewed by a qualified human reviewer for accuracy, clinical soundness, and regulatory currency before publication. Editorial responsibility for every published article rests with Mammologix and with the named author, not with any tool used in producing it. AI is not credited as an author, because authorship carries accountability and a tool cannot hold it.

Patient-facing and clinical-adjacent content

Tier 3 content receives human verification of every clinical reference and every guideline citation regardless of how the draft was produced.

We review this disclosure as AI tools and industry norms evolve.

Corrections

We would rather fix an error visibly than quietly.

When a factual error is identified in published content, we correct it promptly. Substantive corrections—meaning any correction that changes the meaning of a regulatory, methodological, clinical, or statistical claim—are noted at the foot of the article with the date and a description of what changed. Minor typographical and formatting fixes are made without notation.

To report an error, email connect@mammologix.com with the article title and a description of the issue. We will respond, and if you are right, we will say so.

Review cycle

Tier 2 and Tier 3 content is reviewed on a scheduled cycle for regulatory and clinical currency. Content that references a requirement, guideline, or benchmark that has since changed is either updated or withdrawn. Each article displays its last-reviewed date so you can judge for yourself whether it is current enough for your purpose.

Content that is no longer accurate and cannot be readily updated is removed rather than left standing.

Standard disclaimers

Opinion and commentary

Articles designated as opinion or commentary carry the following notice:

Disclaimer: The views expressed in this article are those of the author and do not constitute medical, legal, or regulatory advice. Facilities should consult their own compliance, legal, and clinical leadership before acting on anything discussed here. Patients should not rely on this content for personal health decisions and should discuss their screening, diagnostic, and follow-up care directly with their own physician or care team.

All content

Mammologix content is provided for educational and operational purposes. It is not medical advice, legal advice, or regulatory advice, and it does not create a consulting or advisory relationship. Facilities remain responsible for their own compliance obligations. Regulatory requirements vary by jurisdiction and change over time, and nothing published here relieves a facility of the obligation to verify current requirements with the FDA, its accreditation body, or its own counsel.

Patients

If you are a patient reading this site, please understand that Mammologix supports the operational side of breast imaging facilities. We are not your care team, we cannot access or interpret your results, and we cannot answer questions about your individual care. Please direct those questions to the facility that performed your imaging or to your own physician.

Questions about this policy

Email connect@mammologix.com or call (800) 739-6919.